Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Chemomab Therapeutics Ltd ADR (NQ: CMMB ) 1.544 +0.034 (+2.25%) Streaming Delayed Price Updated: 10:44 AM EDT, Oct 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 19,692 Open 1.480 Bid (Size) 1.530 (21) Ask (Size) 1.550 (8) Prev. Close 1.510 Today's Range 1.480 - 1.579 52wk Range 0.4200 - 2.550 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Chemomab Therapeutics to Present at October 2024 Investor Conferences October 01, 2024 From Chemomab Therapeutics Via GlobeNewswire Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 03, 2024 Via Benzinga Performance YTD +187.10% +187.10% 1 Month -37.24% -37.24% 3 Month +59.59% +59.59% 6 Month +91.33% +91.33% 1 Year +71.56% +71.56% More News Read More Chemomab Therapeutics to Present at September 2024 Investor Conferences August 28, 2024 From Chemomab Therapeutics Via GlobeNewswire CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024 August 21, 2024 Via InvestorPlace Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 21, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update August 12, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Closing of $10 Million Private Placement July 30, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement July 26, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise July 25, 2024 Via Benzinga Chemomab Therapeutics Announces $10 Million Private Placement July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis July 25, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis June 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference June 06, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Participate in Upcoming Scientific Conferences May 17, 2024 From Chemomab Therapeutics Via GlobeNewswire CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024 May 09, 2024 Via InvestorPlace Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule May 08, 2024 From Chemomab Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session May 06, 2024 Via Benzinga Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference May 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update April 24, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis April 18, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 April 02, 2024 From Chemomab Therapeutics Via GlobeNewswire Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis March 25, 2024 From Chemomab Therapeutics Via GlobeNewswire CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 March 07, 2024 Via InvestorPlace Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
